Document is current

Any future updates will be listed below

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system

Crossref DOI link: https://doi.org/10.1038/s41598-025-99773-4

Published Online: 2025-04-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark